ibandronic acid has been researched along with cinacalcet in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Economidou, D; Ginikopoulou, E; Memmos, D; Minasidis, E; Mitsopoulos, E; Pateinakis, P; Thodis, E; Tsakiris, D; Vargemezis, V; Zanos, S | 1 |
| Ogrin, C | 1 |
1 review(s) available for ibandronic acid and cinacalcet
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for ibandronic acid and cinacalcet
| Article | Year |
|---|---|
Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.
Topics: Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Cinacalcet; Diphosphonates; Female; Femur Neck; Fibrous Dysplasia of Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Male; Middle Aged; Naphthalenes; Pilot Projects; Renal Dialysis; Risk; Teriparatide; Treatment Outcome | 2012 |
Evaluation of parathyroid levels and bone densitometry after cinacalcet treatment in severe primary hyperparathyroidism.
Topics: Alkaline Phosphatase; Bone Density; Calcium; Cinacalcet; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Ibandronic Acid; Naphthalenes; Osteoporosis; Parathyroid Hormone; Phosphates; Vitamin D | 2013 |